Imagine growing a tiny, simplified version of an embryo in a lab dish that acts like a biological simulator. Instead of using animals, scientists use stem cells and AI to guide these 'mini-models' to grow specific parts like hearts or guts. It is like using a high-tech 3D printer, but with living cells, to see how organs form and react to medicine.
Animal testing is often inaccurate for human physiology and ethically controversial. Current organoids are too small, lack blood vessels, and cannot mimic complex multi-organ development.
A system for creating 3D stem-cell models (gastruloids) combined with AI classifiers for growth prediction and microfluidic chips for real-time monitoring.
If you are a drug discovery firm dealing with high failure rates in animal trials — this project developed human gastruloid models that provide a more accurate representation of human physiology. This allows for earlier and more reliable toxicology tests before moving to clinical trials.
If you are a regenerative medicine startup dealing with the lack of complex 3D tissue models — this project developed a method to create vascularized organ precursors. This enables the growth of larger, more realistic tissue structures for transplant research.
If you are a hardware provider dealing with the need for precise cell-culture environments — this project developed closed-loop microfluidic chips for real-time monitoring. This creates a demand for specialized imaging and fluid-control hardware integrated with AI.
Based on available project data, no specific pricing or commercial cost structures are provided as the project is currently in the research and development phase.
The project is working towards stable mouse and human gastruloid protocols and closed-loop systems, but based on available project data, industrial-scale manufacturing has not yet been demonstrated.
Based on available project data, there is no mention of specific patents or licensing agreements, though the consortium is establishing an ethical and regulatory framework for the work.
The project uses machine learning classifiers to predict development and a closed-loop system for real-time monitoring of the gastruloids.
The project period runs from 2022-11-01 to 2027-10-31, suggesting that final results and potential transitions to market will occur toward the end of 2027.
The consortium is heavily academic, consisting of 6 universities and 2 research institutes across 4 countries. With an industry ratio of 0%, the project is currently driven by fundamental science and technical validation rather than commercial go-to-market strategies. This indicates a high potential for future licensing but a current lack of direct industrial application.
Contact Oslo Universitetssykehus HF
Contact us to identify potential licensing opportunities for these AI-guided organ models.
